Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection
Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection
NCT ID: NCT01838915 Phase: PHASE1 Status: COMPLETED Enrollment: 45 Completion: 2018-06
Conditions
HIV
Interventions
Prebiotics+Glutamine, Placebo
Summary
A rapid and almost complete loss of CD4+ T cells from the gut associated lymphoid tissue (GALT) occurs early in HIV infection, with a permanent damage in the intestinal barrier, changes in gut microbiota, increased bacterial translocation and persistent immune activation, changes that are not restored after the initiation of antiretroviral therapy. The investigators hypothesize than an intervention targetting the enterocyte barrier and the gut microbiota might modify the gastrointestinal tract towards a bifidogenic microbiota and improve markers of bacterial translocation, inflammation, immune activation and endothelial dysfunction.
Primary Outcome
Safety